ERBB3 over exp
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ERBB3
Variant over exp
Impact List none
Protein Effect no effect
Gene Variant Descriptions ERBB3 (HER3) over exp indicates an over expression of the Erbb3 (Her3) protein. However, the mechanism causing the over expression is unspecified.
Associated Drug Resistance
Category Variants Paths

ERBB3 over exp

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 over exp prostate cancer sensitive Patritumab deruxtecan Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) inhibited growth of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture and in a patient-derived xenograft (PDX) model, but did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp prostate cancer predicted - sensitive Patritumab Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp breast cancer sensitive Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line overexpressing Erbb3 (Her3) in culture (PMID: 35503762). 35503762
ERBB3 over exp triple-receptor negative breast cancer predicted - sensitive Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic triple-negative breast cancer patients with high ERBB3 (HER3) (>/=75% membrane positivity) levels (n=53), with an objective response rate of 22.6%, disease control rate of 79.2%, with partial response in 22.6% and stable disease in 56.6% of patients, median progression-free survival of 5.5 mo, and median overall survival of 14.6 mo (PMID: 37801674; NCT02980341). 37801674
ERBB3 over exp Her2-receptor positive breast cancer predicted - sensitive Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic ERBB2 (HER2)-positive breast cancer patients with high ERBB3 (HER3) (>/=75% membrane positivity) levels (n=14), with an objective response rate of 42.9%, disease control rate of 92.9%, with partial response in 42.9% and stable disease in 50% of patients, median progression-free survival of 11 mo, and median overall survival of 19.5 mo (PMID: 37801674; NCT02980341). 37801674